Paola Pozzi
Directeur/Membre du Conseil chez Fondazione per la Scuola della Compagnia di San Paolo
Profil
Paola Pozzi is associated with multiple firms and holds the position of Director in Fondazione per la Scuola della Compagnia di San Paolo, Chroma Medicine, Inc., and AAVantgarde Bio Srl.
She is also a Partner at Sofinnova Partners SAS since 2018.
Postes actifs de Paola Pozzi
| Sociétés | Poste | Début |
|---|---|---|
Fondazione per la Scuola della Compagnia di San Paolo
 Fondazione per la Scuola della Compagnia di San Paolo Investment Trusts/Mutual FundsMiscellaneous Fondazione per la Scuola della Compagnia di San Paolo aims to contribute to the effectiveness of the education system. Its activities are directed towards the development of school autonomy such as the promotion of scientific research as well as the collaboration with schools in didactic planning and the expansion of training activities. The company was founded on August 27, 1595 and is headquartered in Turin, Italy. | Directeur/Membre du Conseil | - |
Sofinnova Partners SAS
 Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Private Equity Investor | 01/10/2018 |
AAVantgarde Bio Srl
 AAVantgarde Bio Srl Miscellaneous Commercial ServicesCommercial Services AAVantgarde Bio Srl is a clinical stage biotechnology start-up based in Milan, Italy. The Italian company has developed proprietary adeno-associated viral (AAV) vector platforms that allow for the delivery of large genes for inherited retinal disorders. Co-founded by Professor Alberto Auricchio and originating from the research activities carried out at TIGEM (Telethon Institute of Genetics and Medicine), AAVantgarde's platforms are focused on broadening the application of AAV-based therapies by addressing the limitations of single AAV therapies cargo capacity. Natalia Misciattelli has been the CEO of the company since 2022. | Directeur/Membre du Conseil | - |
Chroma Medicine, Inc.
 Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Fondazione per la Scuola della Compagnia di San Paolo
Fondazione per la Scuola della Compagnia di San Paolo Investment Trusts/Mutual FundsMiscellaneous Fondazione per la Scuola della Compagnia di San Paolo aims to contribute to the effectiveness of the education system. Its activities are directed towards the development of school autonomy such as the promotion of scientific research as well as the collaboration with schools in didactic planning and the expansion of training activities. The company was founded on August 27, 1595 and is headquartered in Turin, Italy. | Miscellaneous |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Finance |
AAVantgarde Bio Srl
AAVantgarde Bio Srl Miscellaneous Commercial ServicesCommercial Services AAVantgarde Bio Srl is a clinical stage biotechnology start-up based in Milan, Italy. The Italian company has developed proprietary adeno-associated viral (AAV) vector platforms that allow for the delivery of large genes for inherited retinal disorders. Co-founded by Professor Alberto Auricchio and originating from the research activities carried out at TIGEM (Telethon Institute of Genetics and Medicine), AAVantgarde's platforms are focused on broadening the application of AAV-based therapies by addressing the limitations of single AAV therapies cargo capacity. Natalia Misciattelli has been the CEO of the company since 2022. | Commercial Services |
Chroma Medicine, Inc.
Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | Health Technology |
